Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia: an updated cost-effectiveness model.

Septiara PutriRyan R NugrahaEka PujiyantiHasbullah ThabranyHanifah HasnurNovita D IstantiDiah Evasarinull Afiatin

Published in: BMC research notes (2022)

Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
public health
healthcare
mental health
newly diagnosed
patient reported outcomes